Trending now:  
Redo-TAVR with balloon-expandable valves: outcomes from a national registry
ORBITA 2: The power of PCI revealed for stable angina
TCT 2023 Highlights
AHA 2023 Highlights
OCT vs angiography in patients with diabetes and complex lesions

Content for healthcare professionals only

News |

Exploring Qiliqiangxin’s Impact on Heart Failure with Reduced Ejection Fraction

23 Oct 2023

The QUEST trial (Chinese Clinical Trials Registry Number ChiCTR1900021929), aimed to investigate the effects of qiliqiangxin, a Traditional Chinese Medicine formulation, in patients with Heart Failure with Reduced Ejection Fraction (HFrEF). A total of 3110 HFrEF patients were randomly assigned to receive qiliqiangxin (n=1555) or a placebo (n=1555). The primary measure of efficacy was a composite event involving cardiovascular (CV) death and re-hospitalization due to deteriorating HF. After a median follow-up period of 18.3 months, the qiliqiangxin group exhibited a 25% occurrence of the primary outcome event, while the placebo group recorded a 30% incidence of the same outcome event.

Learn more about the interesting studies presented at ESC Congress 2023.

For more cardiology research news join our newsletter or follow us on TwitterFacebookLinkedIn or Instagram.


Related Topics

Related Articles